Sirolimus-Coated Balloon Angioplasty Cut Reintervention at 1 Year in Femoropopliteal Disease
Patients with symptomatic femoropopliteal artery disease often enter the endovascular suite with a familiar problem: flow-limiting plaque, exertional limitation, and a high chance of restenosis after balloon treatment alone. In the SirPAD secondary analysis, sirolimus-coated balloon angioplasty was associated with fewer repeat procedures over 1 year than uncoated balloon angioplasty among patients without tissue loss. The signal centered on durability of the treated segment, not on mortality, which remained low and similar across groups.
The cohort reflects a typical peripheral artery disease population seen in contemporary practice. Among 597 patients, median age was 71 years, 34.7% were women, and the median target-lesion length was 150 mm. More than half of the treated lesions, 53.8%, were total occlusions. These are not trivial lesions; long, obstructive femoropopliteal disease is exactly where plain angioplasty often runs into elastic recoil, dissection, and neointimal hyperplasia during follow-up. A drug-coated strategy aims to blunt the proliferative response that drives restenosis after mechanical vessel injury.
Revascularization Endpoints Favored the Drug-Coated Strategy
The clearest difference emerged in target-lesion revascularization. After 1 year, 50 patients in the sirolimus-coated balloon group, or 17.0%, had undergone TLR compared with 82 patients, or 27.1%, in the control group. The absolute risk difference was -10.1%, with a 95% confidence interval from -16.6 to -3.0. In plain terms, fewer patients needed the same artery treated again within a year when sirolimus was delivered through the balloon surface.
A second endpoint pointed in the same direction. The composite of any amputation or any TLR occurred in 17.7% of patients in the sirolimus-coated balloon group versus 27.1% of control patients, yielding an absolute risk difference of -9.4% with a 95% confidence interval from -16.0 to -2.7. Major adverse limb events were also less frequent, 4.1% versus 8.9%, with an absolute risk difference of -4.8% and a 95% confidence interval from -9.0 to -0.8. These differences are clinically meaningful because they speak to a lower burden of repeat limb intervention, not simply a surrogate imaging signal.
One sentence captures the practical meaning of the dataset: fewer arteries needed another procedure. The mechanism is plausible. Sirolimus inhibits smooth muscle cell proliferation and migration, the biologic response that commonly narrows the vessel again after balloon injury. In femoropopliteal disease, where mechanical stress from leg motion compounds restenotic biology, suppressing neointimal growth can make an observable difference in the rate of repeat revascularization.
Mortality Stayed Similar Despite the Revascularization Signal
All-cause death at 1 year was 3.7% in the sirolimus-coated balloon group and 5.3% in the control group. The analysis does not support a mortality advantage, and it was not designed to establish one. For patients and clinicians, this matters because peripheral intervention trials often produce a pattern in which patency or reintervention improves before any effect on survival becomes visible, if it appears at all. The outcome most immediately affected here was the need for another procedure, not the risk of death within 12 months.
The absence of a survival difference should not be read as a failure of the intervention. Peripheral artery disease treatment in this setting is primarily about symptom relief, walking capacity, patency, and preventing limb deterioration. A therapy can improve the local vascular course without changing short-term mortality, especially in an older population where competing cardiovascular risks remain substantial.
How to Read the Secondary Analysis
This was a secondary analysis of the multicenter, randomized, blinded-endpoint SirPAD trial, and the investigators limited the population to patients with femoropopliteal target lesions and no tissue loss, defined by Rutherford category ≤4 and Fontaine stage ≤III. A further subgroup excluded ischemic rest pain, prior major amputation, and below-the-knee revascularization to focus on lower disease burden. Those restrictions sharpen the clinical question, because the study asked whether a drug-coated balloon has a different effect when the limb has not yet crossed into tissue-loss territory.
Secondary analyses can generate important hypotheses, but they do not carry the same confirmatory weight as a prespecified primary endpoint analysis. The descriptive nature of these results leaves room for chance, patient selection effects, and the usual cautions that accompany subgroup work. Even so, the direction of effect was consistent across limb-related endpoints, which strengthens the clinical plausibility of the finding.
The lesion profile also deserves attention. A median lesion length of 150 mm and a high proportion of total occlusions indicate a substantial anatomic burden, the kind of disease in which restenosis risk is inherently elevated. In that context, a 10-point absolute reduction in repeat intervention is not an abstract statistic; it translates into fewer catheterizations, fewer follow-up procedures, and less disruption for patients already living with mobility-limiting arterial disease.
What This Means at the Bedside
For clinicians treating femoropopliteal artery disease without tissue loss, these data support the idea that a sirolimus-coated balloon may provide better 1-year vessel durability than an uncoated balloon. The signal is strongest for repeat revascularization and related limb events, while death remains unchanged over the observed horizon. That pattern fits the biology of restenosis: the device appears to influence local vascular repair, not the broader systemic cardiovascular risk that drives mortality in peripheral artery disease.
The findings also help frame expectations for patients. A better angiographic or procedural result is valuable only if it reduces the need for another intervention or delays clinical deterioration. Here, the reduction in TLR suggests that sirolimus delivery may accomplish exactly that in a population with exertional symptoms and no tissue loss.
Still, the study stops short of settling the question. The 1-year horizon is brief for a chronic atherosclerotic disorder, and the descriptive secondary design means the results should be viewed as supportive rather than definitive. Longer follow-up and confirmatory primary analyses will be needed to determine how durable the benefit remains and whether any broader limb outcomes eventually separate further.